ABBV - Company ID 0001551152
AbbVie Inc. trades as ABBV and has a market capitalization of $448.37 B, making it the #25 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $61.16B, up 8.6% from the prior year and net income of $4.23B. This page tracks AbbVie Inc. through 1,008 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years AbbVie Inc.'s revenue grew from $25.64B to $61.16B, a compound annual growth rate of 10.1%. Net profit margin compressed from 23.2% to 6.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
AbbVie to Present at the Bank of America Securities Healthcare Conference
The largest companies sharing AbbVie Inc.'s SEC industry classification (pharmaceutical preparations).
AbbVie Inc. (ABBV) has a market capitalization of $448.37 B as of 2026-07-09, ranking #25 among US-listed companies.
AbbVie Inc. reported revenue of $61.16B for fiscal year 2025, an increase of 8.6% year over year.
Yes. AbbVie Inc. reported net income of $4.23B in its latest fiscal year.